Categories: News

Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

HYDERABAD, India, August 1, 2025 /PRNewswire/ — Zenara Pharma Private Limited (“Zenara”), a Biophore company, today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride Capsules, 150 mg and 200 mg. This approval marks the first FDA-approved generic equivalent of the reference listed drug marketed by Almatica Pharma, LLC.

- Advertisement -

The product has also been granted Competitive Generic Therapy (CGT) designation by the FDA. As the first approved applicant under this pathway, Zenara’s ANDA has secured 180 days of marketing exclusivity in the U.S., which commenced with the product’s launch1.

- Advertisement -

Sertraline Hydrochloride Capsules are classified as selective serotonin reuptake inhibitors (SSRIs) and are indicated for the treatment of Major Depressive Disorder (MDD) in adults and Obsessive-Compulsive Disorder (OCD) in adults and pediatric patients aged six years and older.

- Advertisement -

Commenting on the milestone, Dr. Srinivas Arutla, CEO of Zenara Pharma Pvt. Ltd., said:

- Advertisement -

“Receiving the first generic approval for Sertraline Hydrochloride Capsules highlights Zenara’s strong R&D capabilities and operational excellence. We remain committed to our mission of delivering to patients, early access to high-quality, affordable pharmaceuticals.”

- Advertisement -

According to IQVIA™ sales data for the 12-month period ending June 2025, U.S. sales of the reference product totaled approximately $35.5 million.

- Advertisement -

About Zenara: 
Zenara Pharma Private Limited – a Biophore company, is a vertically integrated pharmaceutical company, committed to delivering high-quality pharmaceuticals that are safe, effective, and affordable to patients. Zenara is an industry leader in Research and Development and Manufacturing of Affordable and Quality finished dosage pharmaceutical Products. Zenara is focused on the therapeutic areas of Neurology, Orphan Drugs, Complex Products, Women’s health, Cardiology, Imaging, and Contrast Agents among others. For more information, please visit us on the web, or connect with us on our LinkedIn page.
*All brand names and trademarks are the property of their respective owners

- Advertisement -

1 U.S. FDA, Competitive Generic Therapy Approvals

- Advertisement -

Logo- https://mma.prnewswire.com/media/2742318/Zenara_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/zenara-pharma-receives-us-fda-approval–for-first-generic-of-sertraline-hydrochloride-capsules-with-180-day-cgt-exclusivity-302519326.html

- Advertisement -
PRNW Agency

Recent Posts

Tradewind Finance Provides USD 3.5 Million Credit Facility for Hong Kong Subsidiary of Leading German Shirt Company

MÖNCHENGLADBACH, Germany, Oct. 23, 2025 /PRNewswire/ -- International trade finance company Tradewind Finance today announced a…

40 minutes ago

All-in-One Excellence: Huion Kamvas Pro 24 (Gen 3) – The Ultimate Drawing Display for Creatives

LOS ANGELES, Oct. 22, 2025 /PRNewswire/ -- Huion officially releases the highly anticipated Kamvas Pro…

40 minutes ago

Xinhua Silk Road: Chinese liquor maker Wuliangye wins 2025 EFQM Global Award

BEIJING, Oct. 23, 2025 /PRNewswire/ -- Chinese liquor maker Wuliangye Yibin Co., Ltd. won the 2025…

41 minutes ago

World’s Leading Nutrition Researchers Discuss Future Lines of Research on Nuts and Dried Fruit at NUTS 2025

REUS, Spain, Oct. 22, 2025 /PRNewswire/ -- Leading health researchers from around the world have…

41 minutes ago

Visionary Entrepreneur Mohit Kamboj Appointed Group CEO of Aspect Global Ventures

In a strategic leadership move, Aspect Global Ventures, one of India’s fastest-growing conglomerates, has appointed…

2 hours ago

Red Hat Named a Leader in Multi Cloud Container Platforms by Independent Research Firm for 2025

Red Hat, the world's leading provider of open-source solutions, today announced that it has been…

2 hours ago